{"name":"Lupin","slug":"lupin","ticker":"LUPIN.NS","exchange":"NSE","domain":"lupin.com","description":"Lupinus, commonly known as lupin, lupine, or regionally bluebonnet, is a genus of plants in the legume family Fabaceae. The genus includes over 199 species, with centres of diversity in North and South America. Smaller centres occur in North Africa and the Mediterranean. They are widely cultivated both as a food source and as ornamental plants, but are invasive to some areas. For instance, lupine has become an ecological problem in Iceland since the beginning of the 21st century.","hq":"Mumbai, India","founded":0,"employees":"24006","ceo":"Vinita Gupta","sector":"Generics / Cardiovascular / Diabetes","stockPrice":2294.1,"stockChange":-4.2,"stockChangePercent":-0.18,"marketCap":"$1.0T","metrics":{"revenue":261505007616,"revenueGrowth":24.3,"grossMargin":70.6,"rdSpend":0,"netIncome":46450401280,"cash":62820900864,"dividendYield":0.53,"peRatio":22.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2006-01-01","label":"Brovana first approved","drug":"Brovana","drugSlug":"arformoterol","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-11-28","label":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE Phase 2 readout (Type 2 Diabetes)","drug":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE","drugSlug":"dapagliflozin-saxagliptin-monohydrate","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Atorvastatin patent cliff ($1.2B at risk)","drug":"Atorvastatin","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Metformin patent cliff ($0.8B at risk)","drug":"Metformin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Lisinopril patent cliff ($0.5B at risk)","drug":"Lisinopril","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"ARMLUPEG","genericName":"PEGFILGRASTIM-UNNE","slug":"pegfilgrastim-unne","indication":"Other","status":"marketed"},{"name":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE","genericName":"DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE","slug":"dapagliflozin-saxagliptin-monohydrate","indication":"Other","status":"marketed"},{"name":"Lupin albuterol HFA MDI","genericName":"Lupin albuterol HFA MDI","slug":"lupin-albuterol-hfa-mdi","indication":"Other","status":"phase_3"},{"name":"Lupin's Pegfilgrastim","genericName":"Lupin's Pegfilgrastim","slug":"lupin-s-pegfilgrastim","indication":"Other","status":"marketed"},{"name":"Oral Capsule Mexiletine (IR)","genericName":"Oral Capsule Mexiletine (IR)","slug":"oral-capsule-mexiletine-ir","indication":"Ventricular arrhythmias","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Brovana","genericName":"ARFORMOTEROL","slug":"arformoterol","indication":"Chronic bronchitis","status":"marketed"},{"name":"Reference Product (Spiriva®)","genericName":"Reference Product (Spiriva®)","slug":"reference-product-spiriva","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"}]}],"pipeline":[{"name":"Brovana","genericName":"ARFORMOTEROL","slug":"arformoterol","phase":"marketed","mechanism":"Brovana works by activating the beta-2 adrenergic receptor to relax airway muscles and improve breathing.","indications":["Chronic bronchitis","Chronic obstructive lung disease","Pulmonary emphysema"],"catalyst":""},{"name":"ARMLUPEG","genericName":"PEGFILGRASTIM-UNNE","slug":"pegfilgrastim-unne","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE","genericName":"DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE","slug":"dapagliflozin-saxagliptin-monohydrate","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Lupin albuterol HFA MDI","genericName":"Lupin albuterol HFA MDI","slug":"lupin-albuterol-hfa-mdi","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lupin's Pegfilgrastim","genericName":"Lupin's Pegfilgrastim","slug":"lupin-s-pegfilgrastim","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oral Capsule Mexiletine (IR)","genericName":"Oral Capsule Mexiletine (IR)","slug":"oral-capsule-mexiletine-ir","phase":"phase_3","mechanism":"Mexiletine is a class IB antiarrhythmic agent that blocks cardiac sodium channels to suppress abnormal electrical activity and restore normal heart rhythm.","indications":["Ventricular arrhythmias","Suppression of premature ventricular contractions","Long QT syndrome (certain forms)"],"catalyst":""},{"name":"Reference Product (Spiriva®)","genericName":"Reference Product (Spiriva®)","slug":"reference-product-spiriva","phase":"phase_3","mechanism":"Tiotropium is a long-acting anticholinergic (muscarinic antagonist) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment","Asthma (in combination with beta-2 agonists)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-08","type":"earnings","headline":"Lupin Reports 14.6% YoY Growth in Q3 FY24","summary":"Lupin reported a 14.6% year-over-year growth in revenue for the third quarter of FY24, driven by strong performance in the US and emerging markets.","drugName":"","sentiment":"positive"},{"date":"2023-08-25","type":"deal","headline":"Lupin Acquires US-Based Pharmaceutical Company, Gavis Pharmaceuticals","summary":"Lupin acquired Gavis Pharmaceuticals, a US-based pharmaceutical company, to expand its presence in the US market.","drugName":"","sentiment":"positive"},{"date":"2023-05-26","type":"regulatory","headline":"FDA Approves Lupin's Generic Version of Eliquis","summary":"The US FDA approved Lupin's generic version of Eliquis, a blood thinner used to prevent stroke and blood clots.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNZHdLeHgtem5ua080LU8tbnRZYVBYOGI1UGVBbUV1Vlh4dzZ6bTU0WWtmSVM4N0ZQNmQycGNkdGFLWENjUGxnRkx5TUp2TlR2QjJfOTlOR1YyX0JGNDFDY0xUemJzMllWTDZnRUVBQ3JBOXg4bDFkS2dRb05GTFBSeEtXS2RrS1hmOWU4LU9Tbw?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Lupin Completes Acquisition of VISUfarma - Yahoo Finance Singapore","headline":"Lupin Completes Acquisition of VISUfarma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSXBYODVlX0UwOWR6MlR4R3o2TlRaaXFHdDg4amtZdC1mbV85bFdZLTZUTG1FRllUSlFueVpkYlVXQ2Jod25GX1J5WW0tSEc0ZWRBb2pWUThwU0paN1hlZk1XTzkxNzktTURoYW05SHhPSm95WmdfSWNkWVUyTEJCQWxaVWVZWWlfTkdha1VNOFIwZmV5X2NTcTdCcFpoOUhQODN2RGdXQQ?oc=5","date":"2026-03-31","type":"regulatory","source":"Yahoo Finance","summary":"Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection - Yahoo Finance","headline":"Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQdE1CbjZTZVVHV3ZZOXhvdERKYjN1MDhYUXJCOEdZQXJqSjVsLUd3Z1FxRzRhdGZTYzdlVGF5U3lhTjNYMVdJS3B4LXpheDEyQmVDcnd0UFRUXzJIYkx2aFAwcDkzdFkxbXg1UzZ2cXRHVHZJaUdyWGxpUnRWSm1BTlRVWnVRZVpZU3Q3U3U2bDQxSDQzbVN2dkNDcDM5OE5QSWtwczdlSQ?oc=5","date":"2026-03-25","type":"regulatory","source":"Yahoo Finance","summary":"Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets - Yahoo Finance","headline":"Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPdHY1dzZ0Y2dwYmh3RWE3d09ROGRmQWhYOFBRVURDOG9idGx1MnMxbzZfOHowMXFSOVZMNUp1cG9aT1YxeFd0UjFXeXpfV3lQdGRiVm5EU2tZUlZiN3JXV1NKd201TGRyb3dFMmw2dHBNWDVoTUZjVy1jV2VkdWJqMm9ld3hZdDJVWkRjdnBxVEVyZjJRNE9VRjJmc2hwbnM4aDFwWjY4TS1sMlpOWk9KTmhCdTBONlRNbjlwWGlLUzN4VkJKQ1Q1TWZweVRMbTZRUEJESGpxNVl2MnFoNkE?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry - Whalesbook","headline":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOWHRwTGxhaHZJbk5OQjViVUQ3ZmkwRjdMalNDT1AzOHpSOGdEb29hY21GSmlhWXhrdFFUMFJhOTJzR0Y0RDlkbzduVjZiQVZ4Sy1yODVfTjdQRVctazYtRmg1NmhjWUVCamt2QVhZNk1Wa25hVUFzNHdxVjQ5cUNfcEp4bDVDWDNySkdKZ3g4a0ZSTHVLX2NZLUtFNEY5aVB5WWVGY28wQnZMR1RsV0FUX2NBcXBQWVR1ZWc5enNzOS11M2NHczc1Xzg3NWdEQUl1d3R0UHVGWlVyZTlBUVJ3?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance - Whalesbook","headline":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1jbmFuWnNNV3dSekIzVXFpQ1hYYWRHS0JBWW5Od0xFcDR0OXpjVUtIWHRLMnJycjBVa0RXYlc4Y2ZnaFZ1R21xV09abTJUWHl5U2RRZ2NraGRHWlJhTW9JTjlHUWxKWWVqRklVZUFNM2lLVEluSWktNVVVTQ?oc=5","date":"2026-03-06","type":"pipeline","source":"Yahoo Finance","summary":"Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025 - Yahoo Finance","headline":"Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxORmxlTDl2VW9aenZBRFM2a3Zfdi05aUJ4RXlxY1NVM2dRV3RmS1hjSThEdTdmWGRhZFNveGkzQy1vQS1YcVloSUpCUmJYVTlOOVNGUFNqVTVXbXc3VkdvOGR3US1hOHhLOTdveFlNMm9nbTBUUlJsWGI0U040QmRJZXNueVhjVlo0eUxwclFIQWxiZDEydDJFTGctanM5QVExOFFoc2N4TXlubEpiLURaOEJCU2lURVlyWHBxa3ozRmhLelVTXzVDbTVSdDVEQmxRb2ZXMUN4Y2pRa2JuQWFOUGVBcjBGUVU?oc=5","date":"2026-02-10","type":"patent","source":"Reuters","summary":"India's Lupin settles US patent dispute with Astellas Pharma for $90 million - Reuters","headline":"India's Lupin settles US patent dispute with Astellas Pharma for $90 million","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-10","type":"patent","source":"Medical Dialogues","summary":"Lupin Settles Mirabegron Patent Dispute With Astellas for USD 90 Million, Clears US Sales - Medical Dialogues","headline":"Lupin Settles Mirabegron Patent Dispute With Astellas for USD 90 Million, Clears US Sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPUmJDSmtkUHpqQ1ZuTUs5czQ2RThfYzdHRXZZWk5yU3JXclVrdmF2WldXY0tZSEo0M0Y4cUtJU3l4bzN5elBtdC12dTBud2hwRUlocHdFWlUybllQMlRzS280Q0tObEs0dGsyMzY5dE9oWld4UVRlUHVUeHMxbjgtVGFOQ1VOMXhGN0dodmJCdDNkNTR3VXFudmdRelh6N1NLWS1mNW00bk9LWGVmRk16cjBFdUkwRDRtZUFBdE9EaWRhV25Dc2E3ZktXNlZLYU1EYmtOZmx4NGNFZ0paZzJtdTdCbHJna0d2?oc=5","date":"2026-02-07","type":"pipeline","source":"lupin.com","summary":"Lupin’s subsidiary in South Africa announces Commercial Agreement with Creso Pharma for hemp oil based cannaQIX - lupin.com","headline":"Lupin’s subsidiary in South Africa announces Commercial Agreement with Creso Pharma for hemp oil based cannaQIX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQWjBOMjNvVTdnTy1iQzVwakZYUjNIbHc2dGY3NlF5bHVKTGNaZnNOamlmLUdiRXoxLTRKSTlpai1GSW9rVTFDbjI0YXpxV2ZLTjd1T3RxN1V2U01jUUxHV3ptRjdSLWllTDJiY3BSVkhLQldoNDJiTGdiaEltN1EwNXg4OFFPU1UwbTFiZktWS3oxaUMzcGhIaVJBX1RNSXdBNnh4MmgzWlNhVXFncjdQeFZGSk5adGFKdE55a1BzcmZDeEJaUzJ5aV85dDhUU2VRQlZ5NEt1RUlucWVubFE?oc=5","date":"2025-11-07","type":"regulatory","source":"Reuters","summary":"India's Lupin posts surge in quarterly profit on strong respiratory drugs demand - Reuters","headline":"India's Lupin posts surge in quarterly profit on strong respiratory drugs demand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNenNVOF9oc3BpblBwTGk1OGJ5UnBxNkZMZmN6cTRQZ1FVc29sSWpmLUNfLXZMeHhtaDllT1NrNHRHQUFuSWZHUFhRTEcxeHJGY2xvTjM3NEV0UVRKd2NJWVFabFM1Z1JnMWJNYmpyWjVzUEZ0cG5oUDQ4dnZWSUdwdzczR3FyNHc1VS05VmJxRWVuMVJvRlFFQUxkaW9CV0E1eXdaTm85TURPd1VIVjdvYUMwbGxxVXhmcXBMODkxTQ?oc=5","date":"2025-07-01","type":"pipeline","source":"Reuters","summary":"India's Lupin to spin off consumer healthcare business - Reuters","headline":"India's Lupin to spin off consumer healthcare business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOSUVSQ2JpYjljWGtGcF9kNUU1RVh5UEJ6aktYZ1NQZ0Y3Mjg2Tm55UGIzRFJqSVlHZjJ6MXlrMDJLLXhRMldsZ0dTa01WaWt2dVdLTFgzNkJLUmZ0QVFwc3ZrSTlyUnlGTTE2b3BoYTJ0QURoaWpZZzgyVGRCcDYtc3R2Q2NTM25ZQU9XaFZ2LUp0b1pGb3FrYnVyMU5oU2RQSHVSZV92VGE5dHpCUVZ5MnpZNjh5QUVIT3JKUnhxMWZiV3hzM2FuTjRjd1ByR3hneEptZE9RNl83emx4YUM4b042QmY4NFBPT3Br?oc=5","date":"2020-08-14","type":"regulatory","source":"BioSpace","summary":"Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis - BioSpace","headline":"Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant Response Rate in Female Patients with T","sentiment":"neutral"}],"patents":[{"drugName":"Atorvastatin","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Lisinopril","drugSlug":"lisinopril","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":500000000},{"drugName":"Metformin","drugSlug":"metformin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":800000000}],"drugCount":7,"phaseCounts":{"marketed":4,"phase_3":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sun Pharmaceutical Industries","Cipla Limited","Dr. Reddy's Laboratories"],"therapeuticFocus":["Cardiovascular","Diabetes"],"financials":null,"yahoo":{"currentPrice":2294.1,"previousClose":2298.3,"fiftyTwoWeekHigh":2377.6,"fiftyTwoWeekLow":1836.8,"fiftyTwoWeekRange":"1836.8 - 2377.6","fiftyDayAverage":2260.35,"twoHundredDayAverage":2070.23,"beta":0.28,"enterpriseValue":1049944260608,"forwardPE":23.4,"priceToBook":5.34,"priceToSales":4.01,"enterpriseToRevenue":4.01,"enterpriseToEbitda":15.31,"pegRatio":0,"ebitda":68564451328,"ebitdaMargin":26.2,"freeCashflow":0,"operatingCashflow":0,"totalDebt":62170001408,"debtToEquity":31.5,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":37,"targetMeanPrice":2425.14,"targetHighPrice":2700,"targetLowPrice":1800,"dividendRate":12,"payoutRatio":0.12,"fiveYearAvgDividendYield":0.52,"exDividendDate":1753401600,"insiderHeldPercent":47,"institutionHeldPercent":32.8,"sharesOutstanding":457179111,"floatShares":241864617,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":101.36,"epsForward":97.92,"revenuePerShare":572.69,"bookValue":429.87,"officers":[{"age":57,"name":"Ms. Vinita D. Gupta","title":"CEO & Executive Director"},{"age":59,"name":"Mr. Ramesh  Swaminathan","title":"Executive Director, Global CFO, CRO & Head of API Plus SBU and IT"},{"age":50,"name":"Mr. Nilesh Deshbandhu Gupta","title":"MD & Executive Director"},{"age":null,"name":"Mr. Christoph  Funke","title":"Chief Technical Operations Officer"},{"age":null,"name":"Dr. Shahin  Fesharaki","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Ravi  Agrawal","title":"Sr. Vice President of Investor Relations and M&A"},{"age":null,"name":"Mr. Amit Kumar Gupta","title":"Company Secretary & Compliance Officer"},{"age":null,"name":"Ms. Rajalakshmi  Azariah","title":"Vice President & Global Head of Corporate Communications"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.lupin.com","phone":"91 22 6640 2323"}}